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ABSTRACT 
Although iron homeostasis is essential for brain functioning, the effects of iron levels on 
cognitive performance in older individuals have scarcely been investigated. In the present 
study, serum iron parameters and hemochromatosis (HFE) C282Y genotype were determined 
in 818 older individuals who participated in a 3-year randomized, placebo-controlled, double-
blind trial examining the effects of folic acid on carotid intima-media thickness. All 
participants had slightly elevated homocysteine levels and were vitamin B12 replete. 
Cognitive functioning was assessed at baseline and after 3 years by means of a 
neuropsychological test battery. At baseline, increased serum ferritin was associated with 
decreased sensorimotor speed, complex speed, and information processing speed, and 
increased serum iron was associated with decreased sensorimotor speed. Cognitive 
performance over 3 years was not associated with HFE C282Y genotype or iron parameters. 
In conclusion, serum iron parameters not show a straightforward relationship with cognitive 
functioning, although elevated iron levels may decrease cognitive speed in older individuals 
susceptible to cognitive impairment.  
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INTRODUCTION 
 Cognitive function declines with age, even in otherwise healthy individuals. In the last 
decades, identifying biological determinants of age-related cognitive decline has become an 
increasingly important goal of aging research (1-3). Disturbed iron homeostasis, which may 
be genetically or environmentally determined, has been coined as one such suspected risk 
factor for cognitive decline (4). 
Iron deficiency is the most common nutritional deficiency worldwide, with a 
prevalence of 5-20% among adults in Western countries (5-8). A depletion of body iron stores 
may result from insufficient dietary intake, hampered absorption, or excessive losses (9, 10). 
In addition, regular whole blood donation may also lower body iron concentrations (8).  
As a constituent of various enzymes, iron is essential for several physiological 
functions, including oxygen transport and DNA synthesis (11). The brain in particular has a 
high demand for iron, not only since it is the main oxygen-consuming organ in the human 
body, but also because many neurobiological processes, including myelination, 
neurotransmitter synthesis, and synaptic plasticity, are iron-dependent (12-14). Consequently, 
one of the major symptoms of iron deficiency is reduced cognitive performance (4, 10, 13, 
14).  
Although the effects of iron deficiency on cognitive functioning have frequently been 
investigated in children and young adults (15-19), research performed in older persons is 
rather limited (20-22). Iron deficiency in older individuals may be due to poor dietary habits, 
gastrointestinal malignancies, or diseases characterized by chronic inflammation (9, 23-25).  
Elevated body iron levels might also impair brain functioning. Since body iron 
concentrations tend to increase with age, particularly in women who reached the menopause 
(26), increased iron concentrations are more frequent in older persons as compared to young 
adults; elevated iron levels may be present in up to 20% of community-dwelling individuals 
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aged 50 years or older (6, 8, 27).  
Elevated iron concentrations may also be observed in carriers of the C282Y mutation 
of the hemochromatosis gene (HFE), which causes increased iron absorption (26, 28). The 
HFE C282Y mutation, which has a prevalence of around 10% in communities of Northern 
European descent (28, 29), has been associated with neurodegenerative disorders (12, 30), 
including Parkinson’s disease (31) and Alzheimer’s disease (32, 33).  
Despite the fact that both iron deficiency and elevated iron levels frequently occur in 
older individuals, and are associated with negative effects on cognitive functioning, only a 
small number of studies have investigated the effects of iron parameters on cognitive 
performance in later stages of life. The results of these cross-sectional studies are mixed. 
Whereas Gao and coworkers did not find any associations between plasma iron and cognitive 
functioning (20), Lam et al. found an inverted U-shaped relationship between serum iron and 
cognitive functioning in men, and an inverse relationship in women (22). In addition, La Rue 
and colleagues reported that serum transferrin was positively correlated with cognitive 
performance in older individuals (21).  
The objective of the present study was to examine the cross-sectional and longitudinal 
associations between iron parameters and cognitive functioning in a large sample of healthy 
older adults. This study investigated linear and quadratic associations between serum iron 
parameters and cognitive performance, as well as the relationship between the HFE C282Y 
mutation and cognitive performance.
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METHODS 
Study population 
The study population consisted of 818 men and women who participated in the FACIT 
study. This randomized, double-blind, placebo-controlled trial was originally designed to 
investigate the effects of 3-year folic acid supplementation on the risk of cardiovascular 
disease as measured by carotid intima-media thickness (34). The study sample included a 
relatively large proportion of blood donors (54%), as participants were recruited from blood 
bank registries as well as from municipal registries. At screening, individuals were included if 
between the ages of 50-70 years, and, specifically for women, had reached the menopause at 
least two years prior. Exclusion criteria were plasma total homocysteine concentrations <13 
µmol/L or >26 µmol/L, use of B-vitamin supplements or drugs that could affect 
atherosclerotic progression (e.g. lipid-lowering or hormone replacement therapies), or self-
reported intestinal disease. We also excluded individuals with elevated homocysteine 
concentrations due to factors other than suboptimal folate concentrations, including serum 
vitamin B12 concentrations <200 pmol/L, self-reported medical diagnosis of renal or thyroid 
disorders, or self-reported use of medications that influence folate metabolism. The Medical 
Ethics Committee at Wageningen University approved the study and all participants gave 
written informed consent. 
 
Cognitive functioning 
Cognitive functioning on the domains of memory, sensorimotor speed, complex 
speed, information processing speed, and word fluency was assessed at baseline and at 3-year 
follow-up by means of a neuropsychological test battery, consisting of the Visual Verbal 
Word Learning Task (35), the Stroop Color-Word Interference Test (36), the Concept 
Shifting Test (37), the Letter-Digit Substitution Test (38), and the Verbal Fluency Test (39). 
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A detailed description of the cognitive test battery and the method used for creating cognitive 
performance indices based on the raw test scores can be found elsewhere (34). 
 
Blood measurements 
The iron parameters measured were total serum iron; total iron binding capacity, 
which is a measure of the serum concentration of the iron transport protein transferrin (40, 
41); transferrin saturation, which is expressed as the ratio (×100%) of serum iron 
concentration and total iron binding capacity; serum ferritin, an indicator of total body iron 
stores (42); and non-transferrin bound iron (43, 44).  
At baseline and at 3-year follow-up, fasting venous blood samples were collected, 
centrifuged within 2 hours, and the serum supernatant was stored in multiple aliquots at -
80°C. Within 15 months of storage samples were thawed for serum measurements. Serum 
iron and total iron binding capacity were measured using Hitachi 747 (Roche Diagnostics). 
Serum ferritin was determined on the Immulite 1 of DPC (Diagnostic Product Corporation) 
using a two-site immunometric assay (reference values: 15-190 µg/L for postmenopausal 
women and 15-280 µg/L for men). Non-transferrin bound iron, which was measured at 
baseline only, was determined by a fluorescence-based one step chelation method (45). Serum 
high-sensitivity C-reactive protein was determined at baseline with ELISA using polyclonal 
antibodies (Dako). An automated hematology analyzer (Sysmex) was used to measure serum 
hemoglobin. For active blood donors, blood samples were collected at least six weeks after 
the most recent blood donation.  
 
Genotyping 
Genomic DNA was extracted from whole blood samples using a Qiamp 96 DNA 
blood kit (Qiagen, Venlo, The Netherlands). DNA samples were stored at -80 °C until further 
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analysis. The HFE C282Y genotype was determined by an automated method using minor-
groove binding DNA oligonucleotides (MGB-probes) (46). The presence of a C282Y allele 
was confirmed by conventional polymerase chain reaction (PCR) with restriction fragment 
length polymorphism analysis (47, 48). Apolipoprotein E (APOE) genotype was determined 
as described elsewhere (34). 
 
Other measurements 
Level of education, measured at baseline by classifying formal schooling according to 
the Dutch educational system, was categorized into low/middle/high, i.e. corresponding to 
primary education, junior vocational training, and senior vocational/academic training, 
respectively (49). Alcohol consumption (g/day) and current smoking (yes/no) were 
ascertained at baseline by means of self-report questionnaires, which were reviewed by a 
trained research assistant. Body mass index (BMI, kg/m2) was calculated from height and 
weight, and physical activity was estimated using the Physical Activity Scale for the Elderly 
(50).  
 
Statistical analysis   
Cross-sectional analyses 
The cross-sectional associations between iron parameters and cognitive functioning 
were assessed by means of hierarchical linear regression analysis. The iron parameters 
considered relevant in relation to cognitive performance were total serum iron, ferritin, and 
non-transferrin bound iron. These parameters represent the different sources of iron in the 
blood, i.e. total circulating iron, a reflection of total stored body iron, and circulating iron not 
bound to the plasma transport protein transferrin, respectively (42-44). Transferrin saturation 
and total iron binding capacity were not included in the regression analyses, not only because 
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they are indirect measures of body iron levels, but also because including these variables in 
the statistical models would have introduced multicollinearity.  
Separate regression models were fitted for the five cognitive performance indices. The 
covariates age, sex, level of education, alcohol consumption, smoking, BMI, physical activity, 
C-reactive protein, hemoglobin, and APOE E4 carrier status were entered in step 1, followed 
by the iron parameters in step 2. Similar regression analyses were performed to examine the 
associations between the HFE C282Y mutation and cognitive performance. The variables 
age, level of education, alcohol consumption, smoking, BMI, and physical activity were 
confounders in our study. Although sex, C-reactive protein, hemoglobin, and APOE E4 
carrier status were no actual confounders in our analyses, we included these variables as 
covariates to enable comparison with other studies investigating the associations between 
body iron levels and cognitive performance (6, 22, 51-53). We also tested for a possible 
confounding effect of homocysteine, as all participants had slightly elevated plasma total 
homocysteine levels. However, the results were similar regardless if homocysteine was 
included in the analyses. Therefore, we did not include this variable in the final statistical 
models.  
To examine the possible non-linear relationships between iron parameters and 
cognitive performance, regression models were fitted for each cognitive performance index, 
with quadratic terms for iron parameters as the independent variables, adjusting for covariates 
and linear terms for iron parameters in step 1.  
 
Longitudinal analyses 
First, we tested whether treatment with folic acid was an effect modifier in our dataset, 
as folic acid was found to exert a positive effect on cognitive performance (34), and previous 
research suggested that folate might interact with iron metabolism (54). We found that folic 
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acid supplementation was not an effect modifier in our dataset; the interaction terms for iron 
parameters and treatment condition were not statistically significant (Supplementary Table 1). 
Furthermore, the serum iron parameters did not significantly differ between the placebo group 
and the treatment group at the end of the study (p=0.972 for serum iron and p=0.892 for 
ferritin), indicating that folic acid supplementation did not influence body iron levels in our 
study. Therefore, the longitudinal analyses were performed in the total sample.  
Using linear mixed models we investigated the associations between iron parameters 
and cognitive performance over 3 years of follow-up, adjusting for covariates. This analysis 
method takes into account the correlation between repeated measurements and allows the 
inclusion of participants with missing observations at follow-up (55). Separate models were 
fitted for each iron parameter in relation to each of the five cognitive performance indices. An 
unstructured covariance structure was used. Time (measured in years since baseline) was 
included to estimate the change in cognitive performance over 3 years of follow-up. The 
longitudinal effect of the iron parameters was estimated by the two-way interaction between 
time and the specific iron parameter, which represents the rate of change in cognitive 
performance over 3 years as a function of this iron parameter. The longitudinal associations 
between the HFE C282Y mutation and cognitive performance were examined in a similar 
manner.  
In secondary analyses, we stratified the study population by sex, donor status, and 
APOE E4 carrier status to determine whether the cross-sectional and longitudinal associations 
between iron parameters on the one hand and cognitive functioning on the other differed 
between men and women, blood donors and non-donors, or carriers and non-carriers of the 
APOE E4 allele. One-sample t tests were used to determine whether serum iron, serum 
ferritin, and cognitive functioning changed over the 3-year follow-up period. Chi-square tests 
and independent samples t tests were used to investigate whether the iron parameters serum 
	   11 
iron, total iron binding capacity, and non-transferrin bound iron, as well as the background 
variables age, sex, level of education, alcohol consumption, smoking, BMI, physical activity, 
C-reactive protein, hemoglobin, and APOE E4 status differed between carriers and non-
carriers of the HFE C282Y mutation. Because of heterogeneity of error variances, the non-
parametric Mann-Whitney U test was performed to test for differences in serum ferritin and 
transferrin saturation between carriers and non-carriers of the HFE C282Y mutation. Hardy-
Weinberg equilibrium was assessed using a Chi-square test. Normality of the standardized 
residuals of the regression analyses was ascertained by means of normal P-P plots.  
The statistical power of the cross-sectional and longitudinal analyses was >0.90 (small 
effect size, f 2=0.02). Statistical differences were considered significant at p-values <0.05. All 
analyses were performed using SPSS 16.0 for Apple Macintosh (SPSS Inc., Chicago, IL). 
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RESULTS 
Participants 
Table 1 shows the baseline characteristics of the participants. Forty-three individuals 
(5.3%) showed depleted iron stores, as indicated by serum ferritin concentrations below the 
lower normal limit (i.e. 15 µg/L). Thirty-two individuals (3.9%) showed serum hemoglobin 
concentrations characteristic of anemia according to WHO criteria, i.e. <7.5 mmol/L for 
women and <8.1 mmol/L for men. The combination of both low ferritin and low hemoglobin 
levels, i.e. iron deficiency anemia, was present in only seven participants (0.9%). In total, 
fifty-three participants (6.5%) showed serum ferritin concentrations above the upper normal 
limit (i.e. 190 µg/L for women and 280 µg/L for men). Among non-donors, the prevalence of 
low serum ferritin was 0.8%, and the prevalence of high serum ferritin was 13.1%, and among 
blood donors, these percentages were 11.3% and 0.9%, respectively.  
Eighty individuals were identified as carriers of the HFE C282Y mutation (10.5%); 
two individuals were homozygous (0.3%) and 78 persons were heterozygous (10.2%). The 
allele frequencies of the HFE C282Y polymorphism did not significantly differ from the 
expected distribution predicted by the Hardy-Weinberg equilibrium (p=0.860) and were 
comparable to the frequencies reported in other population-based studies (28, 29). Serum iron, 
transferrin saturation, and non-transferrin bound iron were significantly increased in carriers 
of the HFE C282Y mutation as compared with non-carriers, whereas total iron binding 
capacity was decreased in carriers of the HFE C282Y mutation as compared with non-carriers 
(Table 1). Serum ferritin and hemoglobin concentrations, as well as the background variables, 
did not significantly differ between carriers and non-carriers of the HFE C282Y mutation 
(Table 1). Table 2 presents the serum iron parameters in carriers and non-carriers of the HFE 
C282Y mutation, stratified by APOE E4 carrier status.  
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Cross-sectional associations between serum iron parameters and cognitive functioning 
The regression analyses including quadratic terms for the iron parameters did not 
reveal any curvilinear relationships between iron parameters and cognitive functioning (data 
not shown). Cross-sectional linear regression analyses indicated that higher serum ferritin 
levels were significantly associated with decreased sensorimotor speed, complex speed, and 
information processing speed, after adjustment for age, sex, level of education, alcohol 
consumption, smoking, BMI, physical activity, C-reactive protein, hemoglobin, and APOE E4 
carrier status (Table 3). In addition, higher serum iron was associated with decreased 
sensorimotor speed (Table 3). In order to better understand the strength of the associations, 
when the predictive value of serum iron for cognitive performance is compared to the 
relationship with age in the same regression model, an increase of 10 µmol/L serum iron 
corresponds to a lower performance on sensorimotor speed similar to an individual 5.9 years 
older. Likewise, a 100 µg/L increase in serum ferritin corresponds to the sensorimotor speed 
and information processing speed of someone 1.2 years older and the complex speed of an 
individual 1.3 years older. In contrast to serum iron and serum ferritin, non-transferrin bound 
iron was not significantly associated with cognitive performance. 
The observed associations between iron parameters and cognitive performance did not 
differ between men and women, except for the relationship between ferritin and sensorimotor 
speed, which was significant in men (β=-0.089, p=0.029), but not in women (β=0.048, 
p=0.498). When the analyses were stratified by donor status, only non-donors showed a 
negative association between serum iron and sensorimotor speed (β=-0.313, p=0.003, as 
compared to β=-0.093, p=0.409 in donors), which was stronger than the association found in 
the total sample. Statistical significance of the other associations between iron parameters and 
cognitive performance that were found in the total sample was eliminated upon stratification 
by donor status. Stratification by APOE E4 carrier status showed that the observed 
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relationship between ferritin and sensorimotor speed was significant only in carriers of one or 
two APOE E4 alleles (n=80) (β=-0.150, p=0.023, as compared to β=-0.044, p=0.287 in the 
non-carrier group); in comparison with the total sample, the negative relationship between 
ferritin and sensorimotor speed was more pronounced in APOE E4 carriers. In APOE E4 
carriers, the negative association between serum iron and sensorimotor speed was similar to 
the relationship observed in the total sample, although it was not statistically significant. 
Overall, the cross-sectional associations between iron parameters and cognitive performance 
in the analyses stratified by sex, donor status, or APOE E4 carrier status pointed in the same 
direction as the associations observed in the total sample, with few differences between the 
groups, although they tended not to reach statistical significance. 
In post-hoc analyses, we stratified by serum C-reactive protein concentration (normal 
≤3 mg/dL, elevated >3 mg/dL (56)) to ascertain whether serum ferritin was associated with 
cognitive functioning in the absence of inflammation. Higher serum ferritin predicted slower 
sensorimotor speed (p=0.008), complex speed (p=0.007), and information processing speed 
(p=0.018) in individuals with normal C-reactive protein concentrations (n=659), but not in 
persons with elevated C-reactive protein levels indicative of inflammation (n=144) (p=0.574, 
p=0.777, and p=0.945, respectively).  
 
Longitudinal associations between serum iron parameters and cognitive functioning 
Cognitive performance significantly declined over the 3-year follow-up period on the 
domains of sensorimotor speed (mean change [95% CI] = -0.08 [-0.11; -0.05], p=0.000), 
complex speed (mean change [95% CI] = -0.06 [-0.10; -0.02], p=0.004), and information 
processing speed (mean change [95% CI] = -0.11 [-0.15; -0.08], p=0.000), whereas memory 
improved significantly (mean change [95% CI] = 0.39 [0.34; 0.44], p=0.000) due to the effect 
of procedural learning. Word fluency did not significantly change over 3 years (mean change 
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[95% CI] = 0.03 [-0.03; 0.09], p=0.320). Ferritin concentrations increased significantly over 
the 3-year follow-up period (mean change [95% CI] = 16.6 µg/L [6.7; 26.4], p=0.001), 
whereas serum iron showed a non-significant decrease (mean change [95% CI] =-0.5 µmol/L 
[-1.0; 0.01], p=0.055). Three-year changes in serum iron and ferritin did not differ between 
the two experimental groups (p=0.268 for serum iron and p=0.707 for ferritin), or between 
men and women (p=0.637 for serum iron and p=0.480 for ferritin). In addition, the 
longitudinal changes in serum iron and ferritin did not significantly differ between blood 
donors and non-donors (p=0.965 for serum iron and p=0.088 for ferritin), although blood 
donors showed a larger 3-year increase in ferritin than non-donors (mean change [95% CI] = 
24.4 µg/L [8.1; 40.7] in donors and 7.1 µg/L [-2.4; 16.7] in non-donors). 
Linear mixed models revealed no significant longitudinal associations between any of 
the iron parameters and cognitive functioning (Table 4), implying that the rate of cognitive 
change over 3 years did not vary according to body iron concentrations. However, stratifying 
our analyses by donor status indicated that higher serum iron significantly predicted less 
decline in sensorimotor speed over 3 years in non-donors (parameter estimate = 0.005, 
p=0.010, as compared with parameter estimate = -0.001, p=0.253 in blood donors), and less 
decline in word fluency over 3 years in blood donors (parameter estimate = 0.006, p=0.012, as 
compared with parameter estimate = -0.004, p=0.165 in non-donors), indicating effect 
modification by donor status. Stratification by sex or APOE E4 carrier status did not reveal 
any differences between men and women, or between carriers and non-carriers of the APOE 
E4 allele. Overall, the longitudinal associations between iron parameters and cognitive 
performance in the analyses stratified by sex, donor status, or APOE E4 carrier status were 
fairly inconsistent in terms of size and direction. 
 
Associations between the HFE C282Y mutation and cognitive functioning 
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To investigate the influence of lifelong exposure to elevated iron levels on cognitive 
performance in later life, we assessed the associations between the HFE C282Y mutation and 
cognitive functioning on each of the five domains. The HFE C282Y mutation was not 
associated with cognitive performance in both the cross-sectional and longitudinal analyses 
(Table 5). 
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DISCUSSION 
In the present study, none of the serum iron parameters, nor HFE C282Y genotype, 
were related to cognitive performance over 3 years of follow-up. However, the results from 
the cross-sectional analyses suggest that in older individuals serum ferritin and serum iron 
may be negatively related to the speed of cognitive functioning. Whereas higher ferritin 
concentrations were associated with decreased cognitive functioning across the three different 
speed measures at baseline, serum iron appeared to be negatively related to sensorimotor 
speed only. Memory processes, on the other hand, did not seem to be related to ferritin, nor 
any other serum iron parameter. In addition, non-transferrin bound iron and the HFE C282Y 
mutation were not associated with cognitive functioning in the cross-sectional analyses.  
Carriers of the HFE C282Y mutation tend to show higher body iron concentrations 
than non-carriers (28). As genetic factors cannot be influenced by cognitive functioning, 
investigating the associations between HFE genotype and cognitive performance has the 
benefit of reducing confounding and ruling out the possibility of reverse causation (57). In the 
present study, we found that the HFE C282Y mutation was associated with significantly 
increased concentrations of serum iron and non-transferrin bound iron, as well as a 
statistically non-significant increase in serum ferritin. Contrary to expectation, we did not find 
any associations between HFE C282Y genotype and cognitive functioning. A possible 
explanation for the lack of such a relationship is the relatively small percentage of carriers of 
the HFE C282Y mutation (10.5%), which might have reduced the probability of detecting 
potential associations. In addition, no data were available concerning another common 
polymorphism of the HFE gene, H63D, which has been found to interact with the HFE 
C282Y genotype in determining individual iron levels (28, 58). Future studies investigating 
the associations between HFE genotype and cognitive functioning might increase statistical 
power by including both polymorphisms of the HFE gene in their analyses. Furthermore, it 
	   18 
should be noted that the generalizability of our study was limited by the nature of the study 
population; the present study sample was not representative of the general population, as 
participants had slightly elevated plasma total homocysteine concentrations and were vitamin 
B12 replete.  
Non-transferrin bound iron has been hypothesized to be involved in neurodegenerative 
disorders characterized by iron deposition in the brain (44, 59). The putative relationship 
between non-transferrin bound iron and cognitive performance, however, has not been 
investigated before. The present results do not offer support for an association between non-
transferrin bound iron and cognitive performance or age-related cognitive decline. Serum 
non-transferrin bound iron concentrations are generally very low in healthy individuals, while 
individuals heterozygous for the HFE C282Y mutation show slightly elevated non-transferrin 
bound iron concentrations (60). In hemochromatosis homozygotes, non-transferrin bound iron 
is typically present in much larger amounts (60). However, as the present study included only 
two individuals homozygous for the HFE C282Y mutation, the range of serum non-
transferrin bound iron concentrations might have been too small for any associations with 
cognitive performance to become manifest. In addition, non-transferrin bound iron was only 
measured at baseline, thereby limiting the interpretation of the longitudinal analyses 
investigating the association of this iron parameter with cognitive functioning over 3 years.  
Although elevated serum ferritin concentrations generally reflect increased body iron 
stores (42), serum ferritin levels also tend to be higher in conditions of inflammation, as 
ferritin is an acute-phase reactant (23, 51). In the present study, we controlled for this 
confounding effect of inflammation by including serum C-reactive protein concentration as a 
covariate in the statistical models. Post-hoc analyses showed that the inverse relationship 
between ferritin and cognitive speed was independent of C-reactive protein concentration, 
indicating that the observed cross-sectional association between serum ferritin and cognitive 
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speed could not be attributed to the presence of inflammation.  
The present finding that higher serum ferritin levels were related to slower 
sensorimotor speed in carriers, but not in non-carriers of the APOE E4 allele, suggests that 
APOE E4 carrier status may modify the effect of elevated body iron stores on cognitive 
functioning. Although APOE E4 carrier status has been implicated in age-related cognitive 
decline and neurodegenerative processes (61, 62), it is unclear which mechanisms might be 
responsible for the putative interplay between APOE E4 carrier status and serum ferritin in 
affecting cognitive performance. 
To date, only a few other population-based studies have investigated the relationship 
between iron parameters and cognitive performance in older individuals. These cross-
sectional studies have yielded conflicting results. Whereas Gao and coworkers did not find 
any associations between serum iron and cognitive performance in a relatively small sample 
of 94 men and 94 women (20), La Rue et al. reported a positive correlation between serum 
transferrin and cognitive functioning, i.e. memory, visuospatial skills, and abstract reasoning, 
in a small sample of 67 men and 70 women (21). However, this association was not corrected 
for potential confounders, such as age, sex, BMI, and alcohol consumption.  
A recent cross-sectional study performed by Lam et al. in a large population-based 
sample consisting of 602 men and 849 women, has shown an inverse linear association 
between serum iron and performance on memory tests in older women (22). Interestingly, in 
older men, Lam et al. found an inverted U-shaped relationship between serum iron and 
memory performance. Since we hypothesized that both low and high body iron levels would 
be associated with cognitive impairment, we also expected to find an inverted U-shaped 
relationship between body iron levels and cognitive performance. However, although the 
number of men in our sample (n=586) was comparable to the number of men included in the 
study by Lam and colleagues, thereby yielding similar statistical power, no curvilinear 
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associations became apparent between the iron parameters and cognitive functioning in the 
present study, neither in the total sample, nor after stratification by sex. The lack of 
curvilinear associations in our study may be due to the relatively small percentage of 
individuals with body iron levels below or above the normal limits. Therefore, possible non-
linear associations between iron parameters and cognitive functioning may have remained 
undetected. Indeed, serum iron concentrations in the study by Lam et al. showed higher 
means and a broader range as compared with our study (21.7 ± 7.2 µmol/L in men and 19.4 ± 
6.2 µmol/L in women, as compared with 19.0 ± 6.8 µmol/L in men and 17.4 ± 4.7 µmol/L in 
women in our study).  
It is worth noting that the prevalence of depleted iron stores in our study sample was 
slightly higher than that reported in other population-based studies with a similar age range 
(i.e. 5.3% as compared to 0.3-3%) (6, 27). In addition, our study showed a lower percentage 
of ferritin levels above the upper normal limit than other studies performed in older 
community-dwelling individuals, which used similar or even higher serum ferritin cutoff 
values (i.e. 6.5% as compared with 12-20%) (6, 27). This may be explained by the large 
number of blood donors in our study sample, as regular whole blood donation has been shown 
to lower body iron concentrations (8). Indeed, whereas 0.8% of non-donors showed ferritin 
levels below the lower normal limit and 13.1% showed ferritin levels above the upper normal 
limit, the prevalence among blood donors was 11.3% and 0.9%, respectively.  
Upon stratification of the cross-sectional analyses by donor status, we found that 
higher serum iron was associated with decreased sensorimotor speed in non-donors, but not in 
blood donors. When the longitudinal analyses were stratified by donor status, we found that 
higher serum iron not only predicted less decline in sensorimotor speed over 3 years in non-
donors, but also less decline in word fluency over 3 years in blood donors. Although these 
findings are not unequivocal, they do suggest that donor status may influence the nature of the 
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associations between serum iron parameters and cognitive performance. The underlying 
mechanism has yet to be elucidated. 
We observed a significant increase in serum ferritin concentrations over the 3-year 
follow-up period, which is consistent with earlier reports indicating that body iron stores 
increase with aging (26). Although the difference was not statistically significant, serum 
ferritin showed a greater 3-year increase in donors as compared with non-donors. This 
difference may be related to the potential discontinuation of blood donation in regular whole 
blood donors during the course of the study. Unfortunately, we were not able to verify this 
assumption, as we did not monitor donor status during the 3-year follow-up period. Serum 
iron tended to decrease during the follow-up period, but this change was not statistically 
significant. Although the factors underlying the 3-year change in serum iron are not exactly 
clear, it is worth noting that they are not likely to be due to diurnal variation in serum iron 
levels (63), as we collected the 3-year blood samples at the same time of day as the baseline 
samples.   
In the present study, we used serum iron parameters as a proxy measure for brain iron 
levels, even though the exact correlation between central and peripheral iron levels is unclear. 
Nonetheless, epidemiological studies have found evidence for a positive association between 
the two, by showing a significant correlation between iron concentrations in serum and 
cerebrospinal fluid in older individuals (64). On the other hand, it has also been suggested that 
brain iron levels may be relatively well-isolated from peripheral iron levels, for example in 
carriers of the HFE C282Y mutation (65). Thus, given the inability to measure cerebrospinal 
fluid or brain iron levels in volunteers, the use of serum iron parameters should be considered 
a shortcoming. 
The main strengths of the present study are the use of longitudinal data, the 
measurement of several iron parameters as well as HFE C282Y genotype, the use of a large 
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community-based sample, and a very low attrition rate in the longitudinal phase (2%) (34). In 
addition, the cognitive test battery administered in the present study has been proven a 
sensitive and robust tool for detecting subtle changes in specific domains of cognitive 
functioning (35-39). Furthermore, the inclusion of both men and women, as well as blood 
donors and non-donors in our study, enabled us to investigate the relationship between iron 
parameters and cognitive functioning within these individual groups. The relevance of taking 
into account donor status in population-based studies is emphasized by the present finding 
that regular whole blood donation may modify the associations between iron parameters and 
cognitive performance. Indeed, the lack of documenting donor status might have confounded 
several other population-based studies investigating these associations, including those 
performed by Lam et al. (22), Gao et al. (20), and La Rue et al. (21). 
In conclusion, the lack of any longitudinal associations between iron parameters and 
cognitive performance, as well as the lack of a relationship between HFE C282Y genotype 
and cognitive functioning, suggests that there is no clear-cut relationship between serum iron 
parameters and cognitive functioning or age-related cognitive decline in older community-
dwelling individuals. However, the present study offers indications for a more intricate 
relationship between body iron levels and cognitive performance, which may be present only 
in a subsample of the community, e.g. in individuals carrying the APOE E4 allele.  
To our knowledge, our study is the first to address the putative associations between 
the HFE C282Y mutation and cognitive performance in healthy older individuals, as well as 
the possible interactions between iron parameters and APOE E4 carrier status or donor status 
in relation to cognitive functioning. Prospective studies using large population-based samples 
are needed to further investigate the associations between iron parameters and cognitive 
performance, and to establish whether this association may differ across selected groups, e.g. 
based on sex, donor status, APOE E4 carrier status, or other risk factors associated with 
	   23 
cognitive decline. In addition, more research is necessary to identify the exact mechanisms by 
which iron parameters may influence cognitive functioning. 
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